

# Standard Precautions: The Nurse's Role

3 Contact Hours

Written by: Colleen Garcia, RN, BSN, CLC, CCE

To earn a certificate and contact hours, students must take test and pass with a score of 80% or greater.

## Objectives:

1. Explain the transmission process of common diseases
2. Identify when and how to perform hand washing, the use of PPE, safe injection practices, Respiratory Hygiene/Cough Etiquette, and safe disposal of contaminated equipment and materials
3. Identify when and how to use Standard Precautions, Airborne Precautions, Contact Precautions, Droplet Precautions, and Neutropenic Precautions
4. Explain how to prevent the transmission of common diseases such as influenza
5. Explain how to prevent the occurrence of common diseases and conditions like hospital-acquired pneumonia

## Introduction:

In any group of nurses, there is diversity. We nurses seem to thrive on this diversity among us; but the thing that draws us together is far stronger than our differences, it's our desire to serve others. Think about it, it is you, the nurse, who sits with the HIV+ patient talking and holding their hand, it's you who runs into the isolation room when the patient slips and falls, it is you who cares for your patients with everything you have. This compassion makes you the excellent nurse that you are, it also means that you get to come into contact with over 20 pathogens on any given patient at any time. For this reason, because you are on the front-line, that standard precautions are important enough to take this online course.

## What are Standard Precautions

**Standard precautions** were first established in 1996 by the Centers for Disease Control (CDC) with a goal of preventing the spread of communicable diseases in hospitals and healthcare settings. They have since become one of the cornerstones of infection prevention.

The CDC recommends standard precautions be used by nursing and healthcare workers for the care of all patients at all times, regardless of their diagnosis or presumed infection status. While there are many components of standard precautions, those centered around nursing care include hand hygiene, use of personal protective equipment (PPE), and care and cleaning of the environment.

## Definitions...

It's important to understand terminology when discussing Standard Precautions, so let's review a few terms:

- A **pathogen** is a disease producing microorganism.
- **Transmission** is any mechanism by which a pathogen is spread by a source or reservoir to a host.
- **Reservoir** is any person, animal, plant, soil, substance, or any combination of these in which an infectious agent normally lives and multiplies. The infectious agent depends on the reservoir for survival, and the reservoir must provide a place where it can reproduce itself in such a manner that it can be transmitted to a susceptible host.
- **Susceptibility** is defined as the inability of a host to resist infection with a particular pathogen.
- **The common vehicle** is a contaminated material, product, or substance that serves as an intermediate means by which an infectious agent is transported to two or more susceptible hosts.
- **Colonization** is when an organism is present without host interference or interaction, like normal skin flora.
- **Host**: An organism in which another organism can live and potentially multiply.
- **Infection** is when there are invasion and multiplication by a microorganism. Infection may be local or systemic; it may begin as local and become systemic, and; there may be no apparent host response or clinical signs and symptoms caused by the infection and/or the host response.
- **Infectious disease** is when the infected host shows a decline in wellness due to an infection.
- **Incubation period** is the time between the beginning of an infection and recognition of symptoms.
- **Latency** is the time after primary infection during which the microorganism lives within the host without producing clinical evidence.
- **Virulence** is the degree of pathogenicity of a microorganism, i.e., how easily it can invade a host and the severity of the disease it can cause.

## Transmission

A chain of events is required for infection to occur. These events are a causative organism, a reservoir for the organism, a means to exit the reservoir, a mode of transmission, as susceptible

host, and a mode of entry into the host. Causative organisms may be bacteria, rickettsiae, viruses, protozoa, fungi, or parasites. The characteristics of causative organisms are as follows:

- Pathogenicity: The ability of a microorganism to cause disease.
- Virulence is the degree of pathogenicity of a microorganism, i.e., how easily it can invade a host and the severity of the disease it can cause.
- Invasiveness: The ability of a microorganism to enter into and move through tissue.
- Infectious dose: The number of organisms needed to initiate an infection.
- Organism specificity: Host preference of the infectious agent.
- Antigen variations: The ability of an infectious organism to change its surface proteins in order to escape host defenses.
- Toxigenicity: The capacity to produce toxins.
- Resistance: The ability to develop resistance to antimicrobial agents.

The organism and its reservoir are the sources of infection. The organism must have a means to exit the reservoir. In an infected host, the organisms exit through the respiratory tract, gastrointestinal tract, genitourinary tract, or drainage from a wound. A route of transmission is necessary to connect the source of infection to its new host. Routes of transmission are contact or airborne.

## **Transmission Types:**

### **Contact transmission**

Direct contact: person to person contact.

Indirect contact: Usually contact with a harmless inanimate object. The infected inanimate object is called a fomite. Fomites can survive on objects and surfaces for a long time and be a potential source of infection for weeks and months, e.g., fomites containing norovirus and *Clostridium difficile*.

Droplet contact: Large particles from coughing, sneezing, or talking.

### **Airborne transmission**

Droplet nuclei: Residue of evaporated droplets that remain suspended in the air. Pathogens spread by airborne transmission include

- Mycobacterium
- Tuberculosis
- Varicella

Dust: Particles in the air containing the infectious agent.

# Pathogens

Any agent causing disease.  
Usually a living microorganism.  
Capable of producing infection.  
Poisons like Arsenic would be excluded.

## VIRUSES

Multi-celled but can only reproduce inside a plant, animal, or person.

Hepatitis	SARS
Herpes, Mono	AIDS, HIV
Warts	Influenza
Chicken Pox	Cold Sores
Small Pox	Cold Germs
Bird Flu H5N1	Measles
Norovirus	Tetanus
Yellow Fever	Typhoid
Ebola Hemorrhagic Fever	

## BACTERIA

Tiny one-celled creatures  
Can live inside or outside the body.

Tuberculosis	Pneumonia
Anthrax	Urinary Tract Infection
Staph	Peritonitis
E. Coli	Strep Throat
Typhoid	Stomach Ulcers
Salmonella	Tularemia
Morgellons ?	Lyme Disease

## FUNGI

Multi-celled but plant-like similar to tree fungus.  
Takes nutrition from a plant, tree, or animal.

Ringworm	Yeast Infection
Adv Pneumonia	Histoplasmosis
Candidiasis	Cryptococcosis

## PROTOZOA

One-celled creatures.  
Usually spread through water.

Malaria	Giardiasis
Chagas Disease	Cryptosporidiosis

## PARASITES

Actual complex living organism.  
Can live in intestinal tract or blood stream.

Round Worm	Tape Worm
Morgellons ?	Triginosis

## PROTEIN

Multi-celled but can only reproduce inside a plant, animal, or person.

BSE Mad Cow Disease  
vCJD Disease

Incomplete list gathered from various medical books.

The following table outlines the organism, the mode of transmission and incubation period for most common microorganisms and parasites.

Disease/Condition	Organism	Mode of Transmission	Incubation Period
Acquired immunodeficiency syndrome (AIDS)	Human immunodeficiency virus	Sexual Percutaneous Prenatal  Stage 1  HIV is passed from one person to another. The virus travels through the bloodstream to many different places in the body.	Months to years
Amebiasis	<i>Entamoeba histolytica</i>	Contaminated water Contact with raw vegetables	2-4 weeks, but longer
Chancroid	<i>Haemophilus ducreyi</i>	Sexual	4-7 days
Chickenpox	<i>Varicella zoster</i>	Airborne	10-21 days
Cholera	<i>Vibrio cholerae</i>	Ingestion of water contaminated with human waste	A few hours
Creutzfeldt-Jacob disease	Prion protein	Unknown in most cases	12 months
Cryptococcosis	<i>Cryptococcus neoformans</i> , <i>Cryptococcus gatti</i>	Inhalation, tissue inoculation, gastrointestinal. No person-to-person spread <sup>10</sup>	Unknown
Cyptosporidiosis	<i>Cryptosporidium</i> species	Ingestion of contaminated water Direct contact with carrier	2-10 days, but of 7 days
Cytomegalovirus (CMV)	Cytomegalovirus	Transfusion Transplant Sexual Perinatal Breast milk Contact with mucous membranes, saliva, or urine	Highly infectious Newborns after delivery
Diarrheal diseases	<i>Campylobacter</i> species	Ingestion of contaminated food or water	24-72 hours
	<i>Clostridium difficile</i>	Fecal-oral Efficient transfer by healthcare professionals to patients	Variably incubation period related to use of anti-biotics

Disease/Condition	Organism	Mode of Transmission	Incu
	<i>Salmonella</i> species	Ingestion of contaminated food or drink	12-72 h
	<i>Shigella</i> species	Ingestion of contaminated food or drink Direct contact with carrier	1-2 days
	<i>Yersinia</i> species	Ingestion of contaminated food or drink Direct contact with carrier Blood transfusion (Rare)	4-7 days
Giardiasis	<i>Giardia lamblia</i>	Fecal-oral transmission Ingestion of contaminated water or food  The risk of acquiring <i>Giardia</i> infection from your pet is small. However, there are some steps you can take to lower your risk. <sup>18</sup>	1-3 weeks
Gonorrhea	<i>Neisseria gonorrhoeae</i>	Sexual contact	1-14 days
Hand, foot, and mouth disease	Viruses of the Enterovirus genus	Direct contact with nose and throat secretions, and with feces of infected persons	Not known vary widely
Foodborne hepatitis	Hepatitis A Hepatitis E	Ingestion of contaminated food or drink contaminated with infected fecal material, Direct contact with carrier  Raw or uncooked meat, contact with infected feces	A: 2-6 weeks E: 2-6 weeks
Bloodborne hepatitis	Hepatitis B Hepatitis C Hepatitis D	Blood, semen, and other body fluids, and perinatally Blood, sexual contact, and perinatally Only occurs in people infected with hepatitis B. Percutaneous	B: 6 weeks to 6 months C: Acute infection weeks to months D: Unknown
Herpangina	Coxsackie virus	Direct contact with nose and throat secretions and with feces of infected persons	4-14 days
Herpes simplex	Human herpes virus 1 and 2	Contact with mucous membrane secretions during sexual activity	2 days
Histoplasmosis	<i>Histoplasma capsulatum</i>	Inhalation of airborne spores	3-17 days
Hookworms	<i>Necator americanus</i> <i>Ancylostoma deodenale</i>	Contact with soil contaminated with feces	21-35 days
Impetigo	<i>Staphylococcus aureus</i> (most common), <i>Streptococcus pyogenes</i>	Contact with carrier	4-10 days
Influenza	Influenza virus A, B, or C	Droplet spread	1- 4 days
Legionnaires' disease	<i>Legionellapneumonophila</i>	Airborne from water source	2-12 days longer



Disease/Condition	Organism	Mode of Transmission	Incu
Listeriosis	<i>Listeria monocytogenes</i>	Perinatal Sexual	Unclea days
Lyme disease	<i>Borrelia burgdorferi</i>	Tick bite  Relative sizes of several ticks at different life stages. In general, adult ticks are approximately the size of a sesame seed and nymphal ticks are approximately the size of a poppy seed. <sup>34</sup>	3-30 d
Lymphogranuloma venereum	<i>Chlamydia trachomatis</i>	Sexual	3-30 d
Malaria	<i>Plasmodium vivax</i> <i>Plasmodium malariae</i> <i>Plasmodium falciparum</i> <i>Plasmodium ovale</i>	Bite from genus <i>Anopheles</i> mosquito	7-30 d
Measles	Measles virus	Droplet spread and Airborne	7-14 d
Meningococcal meningitis or bacteremia	<i>Neisseria meningitidis</i>	Contact with pharyngeal secretions, perhaps airborne	1-14 d
Mononucleosis	Epstein Barr virus	Usually by contact with oral and pharyngeal secretions, also by blood and semen during sexual contact, and contact with infected blood or organs. <sup>41</sup>	4-6 we
Mycobacterial diseases (non-tuberculosis) Mycobacterium species	<i>Mycobacterium avium</i> <i>Mycobacterium kansasii</i> <i>Mycobacterium fortuitum</i> <i>Mycobacterium goodnae</i> Other <i>Mycobacterium</i> species	Variable: probably contact with soil, water, or other environmental sources. Not transmissible person-to-person	Variab
Mycoplasma pulmonary tract infections	<i>Mycoplasma pneumonia</i>	Droplet inhalation	1-4 we
Pediculosis	<i>Pediculus humanus capitus</i> (head louse) <i>Pediculus humanus corporis</i> (body louse)	Direct contact	Approx weeks
	Phthirus pubis (crab louse)	Sexual	Approx weeks
Pinworm	<i>Enterobius vermicularis</i>	Direct contact with egg-contaminated articles - Usually fecal-oral	1-2 mo
Pneumocystis pneumonia	<i>Pneumocystis jiroveci</i>	Inhalation	4-8 we

Disease/Condition	Organism	Mode of Transmission	Incu
Pneumococcal pneumonia	<i>Streptococcus pneumoniae</i>	Droplet spread	Probab
Rabies	Rabies virus	Direct contact of virus-laden saliva of a rabid animal into a bite or scratch. Transmission by aerosol and organ transplantation has been reported.	weeks
Respiratory syncytial disease	Respiratory syncytial virus	Self-inoculation by touching mouth or nose after contact with infectious respiratory secretions	2/8 da
Ringworm	<i>Microsporumspecies</i> <i>Trychophytonspecies</i> <i>Epidermophyton floccosum</i>	Direct and indirect contact with lesions	4-14 d
Rocky Mountain Spotted fever	<i>Rickettsia rickettsii</i>	Tick bite	2-14 d
Rotavirus gastroenteritis	Rota virus	Fecal, oral	About
Rubella	<i>Rubella virus</i>	Droplet spread Direct contact	12-23
Scabies	<i>Sarcoptes scabiei</i>	Direct skin	1-4 da previo weeks exposu
Staphylococci	<i>Staphylococcus aureus</i> Coagulase-negative: <i>S. epidermidis</i> <i>S. haemolyticus</i>	Direct contact with draining lesions Auto-infection from colonized nares	Variab
Streptococci	<i>Streptococcus pyogenes</i> groups A with about 80 serologically distinct types	Large respiratory droplets Direct contact with secretions Ingestion of contaminated food	Variab for gro pharyn
Syphilis	<i>Treponema pallidum</i>	Sexual	2-4 we
Tetanus	<i>Clostridium tetani</i>	Entry through broken skin	1 day t month days <sup>62</sup>
Trichinosis	<i>Trichinella spiralis</i>	Ingestion of insufficiently cooked food, especially pork and beef	1-2 da
Tuberculosis	<i>Mycobacterium tuberculosis</i>	Airborne	2-10 w immun weeks sympt



Disease/Condition	Organism	Mode of Transmission	Incu
Typhoid fever	<i>Salmonella typhi</i>	Ingestion of contaminated food or water	Usually range month

**For these organism and parasites to be the most effective to host infection, there must be a susceptibility to the infection. The factors include:**

- Number of organisms to which host is exposed and the duration of exposure
- Age, genetic constitution of host, and general physical, mental, and emotional health and nutritional status of the host
- Status of hematopoietic systems: efficacy of reticuloendothelial system
- Absent or abnormal immunoglobulins
- The number of T lymphocytes and their ability to function

Pregnant healthcare professionals are not known to be at a greater risk of contracting bloodborne infections; however, during pregnancy, the infant is at risk of perinatal transmission.

The organism must have a portal of entry into the host for infection to occur. Portals of entry are:

- Mucous membranes
- Non-intact skin
- Respiratory tract
- Gastrointestinal tract
- Mechanism of introduction (Percutaneous injury or invasive devices).

### **Antibiotic-Resistant Organism**

One cannot discuss micro-organism and parasites without also discussing Antibiotic-resistant organisms that have become an increasingly serious problem in today's world. All microorganism that can cause disease are also capable of developing resistance to antibiotics, let's look at some of the most common ones.

### **Carbapenem-resistant Enterobacteriaceae**

Enterobacteriaceae are gram-negative bacilli that are commonly found in the gastrointestinal tract. Common species of this family that cause infection include:

- Enterobacter
- Escherichia coli
- Klebsiella

Carbapenem-resistant Enterobacteriaceae (CRE) are resistant to treatment with carbapenem family of antibiotics, which include:

- Doripenem
- Ertapenem
- Imipenem
- Meropenem

These antibiotics have traditionally been used to treat pathogens that are resistant to broad-spectrum antimicrobials. The CRE is spread through contact with infected surfaces (e.g. hands or contaminated medical equipment), and infections with CRE are particularly dangerous as they can spread rapidly, and the mortality rate can exceed 40%. Antibiotics that are effective against multi-drug resistant gram-negative bacilli are still being developed, and much research is needed.

CRE infections do not usually occur in healthy individuals; they are more likely to occur in hospitalized patients who have a compromised immune system, patients who are mechanically ventilated, or those who have received multiple antibiotics.

The incidence of CRE infections is increasing. Control and prevention of CRE should be focused on the following seven factors:

1. Identifying colonized patients
2. Screening by taking stool, rectal, and perirectal cultures as well as wound cultures when appropriate
3. Strict adherence to handwashing protocol
4. Environmental cleaning
5. Patient and staff cohorting
6. Staff education
7. Using contact precautions

### **Drug Resistant Staphylococcus Aureus**

Staphylococcus aureus is transmitted primarily via the hands of healthcare professionals as well as with contaminated equipment and surfaces. Transmission is very efficient, and S aureus colonizes the skin and nares easily. Once colonized, the person faces likelihood of infection when invasive procedures are performed.

Methicillin and oxacillin-resistant S aureus (MRSA, ORSA) are common causes of nosocomial infections in hospitals and extended care facilities. Methicillin- and oxacillin-resistant colonization are rarely recognized and MRSA colonization is quite common, so every patient must be assumed to have been exposed to and/or colonized with MRSA/ORSA. In addition, MRSA often contaminates medical equipment such as stethoscopes and environmental surfaces like computer keyboards. Methicillin- and oxacillin-resistant S aureus can produce toxins and invade body tissues. The only effective antibiotic for treating these infections is vancomycin. The Centers for Disease Control and Prevention (CDC) recommends strict adherence to Standard Precautions, correct and appropriate use of personal protective equipment (PPE), appropriate handling of medical devices and laundry, and Contact Precautions should be used if the facility has decided that MRSA is of special clinical or epidemiological significance.

Vancomycin intermediate S aureus (VISA) and vancomycin-resistant S aureus (VRSA) are classified by a lab test. The results of the test is called minimum inhibitory concentration (MIC),

which is the measure of the minimum amount of antimicrobial agent that inhibits bacterial growth in a test tube. Staph bacteria are classified as VISA if the MIC for Vancomycin is 4-8µg/ml, and classified as VRSA if the vancomycin MIC is >16µg/ml. These infections must be reported to the CDC and the state department of health. Patients who are infected with VISA or VRSA should:

- be in a single room
- Contact Precautions and Standard Precautions
- staff education is recommended
- minimize the number of staff caring for the patient
- flag the chart to alert staff of the situation.

### **Vancomycin-Resistant Enterococcus (VRE)**

Enterococcus is a gram-positive bacterium that is normal flora of the gastrointestinal tract and female genital tract. It is a relatively weak pathogen, but it is capable of producing significant infections if the patient is infected with vancomycin-resistant enterococcus (VRE), treatment options for these infections are limited. People at risk for VRE infections include patients previously treated with vancomycin, patients in intensive care, patients who are immunocompromised, patients who have abdominal or chest surgery, and patients with in-dwelling IV or urinary catheters. Vancomycin-resistant enterococcus is transmitted primarily via the hands of healthcare professionals and by direct contact with contaminated equipment and surfaces. There have been many approaches used to control VRE in healthcare settings, and the methods used should be tailored to the clinical setting, the specific patient/patients involved, and the epidemiological characteristics of the situation. Contact precautions and standard precautions should be used to prevent transmission of VRE.

### **Multidrug-Resistant Tuberculosis (MDR-TB)**

Tuberculosis (TB) is caused the Mycobacterium tuberculosis bacteria, and it is one of the oldest recognized infectious diseases. Multidrug-resistant tuberculosis is resistant to the following drugs:

- Isoniazid
- Rifampin
- Fluoroquinolones
- And at one of the three second-line injectable drugs used to treat TB.

The incidence of MDR-TB has increased in recent years due to poor compliance with prescribed drug regimens, inappropriate/incorrect prescribing, patient risk factors, and characteristics of specific TB strains. Infection control measures should include separation of the infected patient/patients, using Standard Precautions, Respiratory Hygiene/Cough Etiquette, minimal hospitalization time proper ventilation, and staff use of particulate respirators. Airborne Precautions are required.

### **Drug-Resistant Streptococcus pneumonia**

*Streptococcus pneumoniae* is a pathogen that is commonly found in the upper respiratory tract. Infections with this pathogen are a common cause of pneumonia, meningitis, sepsis, bacteremia, and otitis media and a leading cause of morbidity and mortality. The elderly and the very young are the most susceptible. Transmission is from infected respiratory droplets, and it can be spread by coughing, sneezing, close contact, or contact with infected droplets. Penicillin-resistant and multidrug-resistant strains of this pathogen have begun to emerge and are widespread in some communities. A vaccine for the most common serotype of *S pneumoniae* is available but underutilized. Contact Precautions, Droplet Precautions, and Respiratory hygiene/Cough Etiquette should be used when caring for patients who are infected with this pathogen.

### **Drug-Resistant *Acinetobacter***

*Acinetobacter* is a bacterium that is usually found in the soil and water, and on the skin of healthy people. People who are susceptible to infections with drug-resistant *Acinetobacter* are usually immunocompromised and/or have chronic lung disease or diabetes. Outbreaks of pneumonia, urinary tract infections, wound infections and blood infections from *Acinetobacter* occur in areas of healthcare facilities where very sick patients are cared for like intensive care units. People on ventilators, patients who have prolonged hospitalization, patients who have had an invasive procedure (e.g. insertion of a central line catheter) and patients who have open wounds are at greater risks. The morbidity and mortality rates associated with drug-resistant *Acinetobacter* infections are very high, and outbreaks of these infections in healthcare facilities are very difficult to control. Contact transmission is the primary way that *Acinetobacter* is spread, so Contact Precautions and Standard Precautions with special attention to hand washing resistant *Acinetobacter* may need to be isolated, or their placement in the facility should be carefully considered.

### **Preventing the Exposure to Infectious Pathogens**

Controls are incorporated into the healthcare work setting to avoid or reduce exposure to potentially infectious materials. Healthcare associated transmission is the transmission of microorganisms that are likely to occur in a healthcare setting, and it can be reduced by using engineered controls, safe injection practices, and safe work practices. Engineering controls are equipment, devices, or instruments that remove or isolate a hazard. Safe injection practices are equipment and practices that allow the performance of injections in an optimally safe manner for patients, healthcare providers, and others that reduce exposure to injury and/or infection. Work practice controls change practices and procedures to reduce or eliminate risks.



## Standard Precautions

And finally, we get to the reason why you are going through this course. Standard Precautions are strategies for protecting healthcare professionals from occupational transmission of organisms; Standard Precautions also prevents patient-to-patient transmission and staff-to-patient transmission. Standard Precautions assume that all pre-existing patient infections cannot be identified. The primary underpinning of Standard Precautions is that all body fluids and secretions should be considered potentially infectious, and barrier precautions should be used routinely to protect from all sources of potential infection. Standard Precautions apply to nonintact skin and mucous membranes, blood, and all body fluids, secretions, and excretions, except for sweat (In certain circumstances even sweat can be considered infectious). In some cases, e.g., with certain pathogens such as HIV, some body fluids such as vomit are only considered to be a risk for disease transmission if they contain visible blood. Additional precautions are based on highly transmissible or epidemiologically important pathogen. Transmission based precautions (isolation) are Airborne, Droplet, and Contact Precautions.

Standard Precautions has six different elements:

- Hand washing
- Use of Personal protective equipment
- Safe and proper disposal of contaminated material and equipment
- Safe injection practices
- Respiratory Hygiene/Cough Etiquette
- Use of mask for procedures like insertions of catheters or injections into spinal or epidural spaces via lumbar puncture.

The new elements of Standard Precautions that have been added since they were formulated were designed to focus on patient protection. These elements are Respiratory Hygiene/Cough Etiquette, safe injection practices, and use of masks for insertion of catheters or spinal or epidural spaces via lumbar puncture.

**Let's look a little closer at a few of these Standard Precautions:**

## **Respiratory Hygiene/Cough Etiquette**

Respiratory Hygiene/Cough Etiquette is a strategy to reduce transmission of respiratory infections at the first point of entry into a healthcare setting. There are signs used to educate both patients and families about Respiratory Hygiene/Cough Etiquette protocol that are posted at entry areas. The instructions are simple ones and state that persons with cough, congestion, rhinorrhea, or increased respiratory secretions should do the following:

- Cover the mouth and nose when coughing or sneezing.
- Dispose of used tissues promptly.
- Use surgical mask if coughing and if tolerated.
- Wash hands after contact with respiratory secretions.
- Separate at least three feet from persons with respiratory infections in common areas when possible.

Although the effectiveness of Cough Etiquette techniques has been questioned, it is still considered to be a mandatory part of infection control and its use among the lay public can be increased by education.

Healthcare personnel should observe Droplet Precautions when caring for patients who have signs and symptoms of a respiratory infection and for whom Respiratory Hygiene/Cough Etiquette is needed. Healthcare personnel who have a respiratory infection are advised to avoid direct patient contact, especially contact with high-risk patients. If this is not possible, then a mask should be worn while providing patient care.

## **Safe Injection Practice**

Needle stick and sharps injuries are a common occurrence in healthcare. The World Health Organization (WHO) "reports in the World Health Report 2002, that of the 35 million health-care workers, 2 million experience percutaneous exposure to infectious diseases each year. It further notes that 37.6% of Hepatitis B, 39% of Hepatitis C and 4.4% HIV/AIDS in Health-Care Workers around the world are due to needlestick injuries. The CDC estimates that 350,000 sharps injuries occur each year, and these injuries are a potential cause for transmission of, and infection with Hepatitis B virus (HBV), hepatitis C (HCV), human immunodeficiency virus (HIV), and more than 20 other pathogens. Infections with each of these pathogens are potentially life threatening but they are also preventable. Literature reviews and individual studies have shown that compared to other health care workers, nurses are especially at risk for needle stick injuries, but housekeepers, physicians, laboratory staff, and other people who work in healthcare suffer these injuries as well.

One serious bloodborne infection can cost more than a million dollars for medications, follow up laboratory testing, clinical evaluation, lost wages, and disability payments, as well as the human costs after an exposure are immeasurable. Employees who have been exposed to a dangerous pathogen such as HIV may experience anger, depression, fear, anxiety, difficulty with sexual relations, difficulty sleeping, problems concentrating, and doubts regarding their career choice. This emotional effect can be a long lasting and have devastating effects, even after a low-risk exposure that does not result in infection.

Percutaneous injuries can be avoided by eliminating the unnecessary use of needles, using devices with safety features, and promoting education and safe work place practices for handling needles and related systems. Since 1993, the use of engineered sharps devices has increased while the use of conventional sharps devices has decreased.

Vigorous efforts to prevent needle stick and sharps injuries have increased awareness of and use of safe injection practices, and improved equipment have helped to decrease the number of these injuries. The Needle Stick Prevention and Safety Act of 2000 was one such effort that mandated the use of engineered needle and sharps.

The following chart by the CDC reviews the nine steps for safe administration:



No.	Recommendation
1	Use aseptic technique when preparing and administering
2	Cleanse the access diaphragms of medication vials with into the vial
3	Never administer medications from the same syringe to changed or the injection is administered through an interv
4	Do not reuse a syringe to enter a medication vial or soluti
5	Do not administer medications from single-dose or single of intravenous solution to more than one patient
6	Do not use fluid infusion or administration sets (e.g., i patient
7	Dedicate multi-dose vials to a single patient whenever po for more than one patient, they should be restricted to a c not enter the immediate patient treatment area (e.g., c patient hemodialysis station)
8	Dispose off used syringes and needles at the point of use puncture-resistant and leak-proof
9	Adhere to "national" requirements for protection of h blood-borne pathogens

Content source: CDC. Guide to Infection Prevention for Outpatient  
Safe Care. <http://www.cdc.gov/HAI/pdfs/guidelines/standards-of->

# THREE THINGS

## you need to know about injection safety:

1. Needles and syringes are single use devices. They should not be used for more than one patient or reused to draw up additional medication.
2. Do not administer medications from a single-dose vial or IV bag to multiple patients.
3. Limit the use of multiple-dose vials and dedicate them to a single patient whenever possible.

### Handwashing

Handwashing is the single most effect method for preventing patient-to-patient, patient-to-staff, and staff-to-patient transmission of microorganisms, and it is one of the foundations of infection control.

Hands should be washed, or alcohol-based rubs should be used:

- Before and after patient care
- Between patient contacts
- After gloves are removed
- After contact with blood, body fluids, secretions, mucous membranes, excretions, and contaminated equipment
- After contact with inanimate objects and medical equipment in the immediate vicinity of a patient
- After using the bathroom
- Before eating
- In certain situations, such as between tasks on the same patient to prevent cross contamination


Improved adherence to hand hygiene, (hand washing, use of alcohol-based hand rubs) have been shown to terminate outbreaks in healthcare facilities, to reduce transmission of antimicrobial resistant organisms such as MRSA and reduces overall infection rates.

However, despite the unequivocal evidence of the effectiveness of hand hygiene and mandatory hand hygiene education, healthcare professionals' compliance with hand hygiene protocols is often very low, at times <30%. There are many reasons why healthcare professionals are non-compliant with hand hygiene protocols, such as perceived lack of time, perceived inconvenience, high work load, and poor staffing. Interventions for improving compliance with hand hygiene protocol can increase compliance, and both the CDC and the WHO have published advice and guidelines for improving hand hygiene compliance. As part of these recommendations, the CDC is asking healthcare facilities to develop and implement a system for measuring improvements in adherence to hand hygiene recommendations. Some of the suggested performance indicators include periodic monitoring of hand hygiene adherence and providing feedback to personnel regarding their performance, monitoring the volume of alcohol-based hand rub used/1000 patient days, monitoring adherence to policies dealing with artificial nails, and focused assessment of the adequacy of healthcare personnel hand hygiene when outbreaks of infection occur.

The diagram below illustrates proper hand washing technique as per Saraya LTD, a leading hand hygiene company in Japan:



## 1 Wash



1 Wet the hands



2 Take an adequate amount of liquid soap



3 Rub hands to lather



4 Rub the back hand with the opposite palm




6 Rub each thumb clapsed in the opposite palm



7 Rub fingertips in the opposite palm



8 Scrub the wrists



9 Rinse well with running water

In addition to traditional handwashing with soap and water, the CDC recommends the use of alcohol-based cleansers by healthcare personnel who perform patient care because they address some of the obstacles that healthcare professionals face when taking care of patients and frequently washing their hands. Alcohol-based rubs have been shown to be very effective, in most cases as effective as soap and water. They significantly reduce the number of

microorganisms on skin, they are fast acting, and they cause less skin irritation than soap and water. When using an alcohol-based hand rubs, apply the product to the palm of one hand and rub your hands together, covering all surfaces of the hands and fingers until the hands are dry, approximately 20 seconds. It is possible for health care professionals can develop contact dermatitis due to alcohol-based hand rubs, but it is very uncommon. However, with increased use of these products by healthcare personal, it is likely that true allergic reactions to these products will occasionally by encountered. Alcohol-based hand rubs take less time to use than traditional soap and water methods, 20 seconds versus 40-80 seconds. In addition, hand rub dispensers can be mounted almost anywhere, unlike a sink and a water tap.

It's important to note that the use of proper hand hygiene does not eliminate the need for gloves. Gloves can significantly reduce hand contamination, prevent cross contamination, and protect patients and healthcare personnel from infection. It's the improper us of gloves that can greatly increase hand contamination. Gloves must be removed after patient contact and a new pair put on for each new patient contact, and they should be replaced if they are torn, damaged, or grossly soiled.

Healthcare personnel should avoid wearing artificial nails and keep natural nails less than one-quarter of an inch long if they care for patients at high-risk of acquiring infections, such as in the intensive care units or transplant units.

Handwashing with soap and water remains a sensible strategy for hand hygiene in non-healthcare settings and its use in these situations is recommended by the CDC and other experts.

## **Conclusion**

As we started with this course, we will also end...with you. Healthcare professionals have an obligation to adhere to scientifically accepted standards for infection control and responsibility to monitor the infection control practices of subordinates. The correct incorporation of work practice controls and engineering controls help to avoid or reduce exposure to potentially infectious materials and hazards. Compliance with environmental infection control measures will decrease the risk of healthcare related infections among patients, especially the immunocompromised, and among healthcare professions.

## **References:**

1. New York State (2008). Department of Health. Healthcare Provider Infection Control Training. ([Visit Source](#)) Accessed May 19, 2017.
2. New York State Department of Health and State Education Department (2010). Infection Control Training Syllabus – 2010. ([Visit Source](#)). Accessed May 19, 2017.

3. New York State Education Department. Rules of the Board of Regents. Part 29, Unprofessional Conduct (October 5, 2011). Section 29.2(a) 13. ([Visit Source](#)). Accessed May 19, 2017.
4. CDC: HIV/AIDS. April 10, 2017. ([Visit Source](#)). April 10. Accessed May 19, 2017.
5. CDC. Parasites – Amebiasis – Entamoeba histolytica infection. July 20, 2015. ([Visit Source](#)). Accessed May 19, 2017.
6. Copeland NK, Decker CF. Other sexually transmitted diseases chancroid and donovanosis. *Dis Mon.* 2016;62(8):306-313. doi: 10.1016/j.disamonth.2016.03.016.
7. CDC. Chickenpox (Varicella). June 13, 2016. ([Visit Source](#)). Accessed May 19, 2017.
8. CDC. Cholera - Vibrio cholerae infection. October 27, 2014. ([Visit Source](#)). Accessed May 19, 2017.
9. Manix M, Kalakoti P, Henry M, et al. Creutzfeldt-Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy. *Neurosurg Focus.* 2015 Nov;39(5): E2. doi: 10.3171/2015.8.FOCUS15328.
10. Maziarz EK, Perfect JR. Cryptococcosis. *Infect Dis Clin North Am.* 2016;30(1),179-206. doi: 10.1016/j.idc.2015.10.006.
11. CDC. Parasites - Cryptosporidium (also known as "Crypto"). February 20, 2015. ([Visit Source](#)). Accessed May 21, 2017.
12. CDC. Cytomegalovirus (CMV) and Congenital CMV Infection. June 17, 2016. ([Visit Source](#)). Accessed May 21, 2017.
13. Kaakoush NO, Castaño-Rodríguez N, Mitchell HM, Man SM. Global epidemiology of Campylobacter infection. *Clin Microbiol Rev.* 2015;28(3),687-720. doi: 10.1128/CMR.00006-15.
14. Curry SR. Clostridium difficile. *Clin Lab Med.* 2017;37(92):341-369. doi: 10.1016/j.cll.2017.01.007.
15. CDC. Salmonella. ([Visit Source](#)). August 25, 2016. Accessed May 21, 2017.
16. CDC. Shigella – Shigellosis. ([Visit Source](#)). March 31, 2017. Accessed May 21, 2017.
17. CDC. Yersinia enterocolitica (Yersiniosis). ([Visit Source](#)). May 25, 2016. Accessed May 21, 2017.
18. CDC. Parasites – Giardia. ([Visit Source](#)). July 21, 2015. Accessed May 21, 2017.
19. CDC. Gonorrhea. ([Visit Source](#)). October 28, 2016. Accessed May 21, 2017.
20. Koh WM, Bogich T, Siegel K, et al. The epidemiology of hand, foot and mouth disease in Asia: A systematic review and analysis. *Pediatr Infect Dis J.* 2016;35(10), e285-e300. doi: 10.1097/INF.0000000000001242.
21. CDC. Viral hepatitis. ([Visit Source](#)). August 27, 2015. Accessed May 21, 2017.



22. CDC. Viral hepatitis. ([Visit Source](#)). August 28, 2015. Accessed May 21, 2017.
23. CDC. Viral hepatitis. ([Visit Source](#)). May 23, 2016. Accessed May 21, 2017.
24. CDC. Viral hepatitis. ([Visit Source](#)). October 17, 2016. Accessed May 21, 2017.
25. Gompf SG. Herpangina. eMedicine. August 15, 2016. ([Visit Source](#)). Accessed May 21, 2017.
26. Jaishankar D, Shukla D. Genital herpes: Insights into sexually transmitted infectious disease. *Microb Cell*. 2016;3(9):438-450. doi: 10.15698/mic2016.09.528.
27. CDC. Fungal diseases. November 21, 2015. ([Visit Source](#)). Accessed May 21, 2017.
28. Brunet J, Lemoine JP, Lefebvre N, et al. Bloody diarrhea associated with hookworm infection in traveler returning to France from Myanmar. *Emerg Infect Dis*. 2015;21(10):1878-1879. doi: 10.3201/eid2110.150695.
29. CDC. Parasites – Hookworm. January 10, 2013. ([Visit Source](#)). Accessed May 21, 2017.
30. Ostrovsky DA. Impetigo. DynaMed Plus, June 15, 2016. ([Visit Source](#)). Accessed May 21, 2017.
31. CDC. Influenza (Flu). ([Visit Source](#)). May 25, 2016. Accessed May 21, 2017.
32. CDC. Legionella (Legionnaires' Disease and Pontiac Fever). July 18, 2016. ([Visit Source](#)). Accessed May 21, 2017.
33. CDC. Lyme Disease. October 26, 2016. ([Visit Source](#)). Accessed May 21, 2017.
34. CDC. Lyme Disease. November 15, 2011. ([Visit Source](#)). Accessed May 23, 2107.
35. CDC. Lyme Disease. October 26, 2016. ([Visit Source](#)). Accessed May 23, 2017.
36. O'Byrne P, MacPherson P, DeLaplante S, Metz G, Bourgault A. Approach to lymphogranuloma venereum. *Can Fam Physician*. 2016;62(7):554-558. PMID: 27412206.
37. CDC. Malaria. October 7, 2015. ([Visit Source](#)). Accessed May 21, 2017.
38. CDC. Malaria. March 1, 2016. ([Visit Source](#)). Accessed May 21, 2017.
39. CDC. Measles. February 17, 2015. ([Visit Source](#)). Accessed May 21, 2017.
40. DynaMed Plus. Meningococcal disease. DynaMed Plus, May 17, 2017. ([Visit Source](#)). Accessed May 21, 2017.
41. CDC. Epstein-Barr Virus and Infectious Mononucleosis. September 14, 2016. ([Visit Source](#)). Accessed May 21, 2017.
42. CDC. Mycoplasma Pneumoniae. March 15, 2016. ([Visit Source](#)). Accessed May 21, 2017.
43. CDC. Parasites – Lice \_ Head Lice. September 1, 2015. ([Visit Source](#)). Accessed May 24, 2017.



44. CDC. Parasites – Lice \_ Head Lice. September 24, 2013. ([Visit Source](#)). Accessed May 24, 2017.
45. CDC. Parasites: Lice. Frequently Asked Questions. September 24, 2013 ([Visit Source](#)). Accessed May 24, 2017.
46. CDC. Parasites – Lice – Pubic “Crab” Lice. September 24, 2013. ([Visit Source](#)). Accessed May 24, 2017.
47. CDC. Parasites - Enterobiasis (also known as Pinworm Infection). January 10, 2013. ([Visit Source](#)). Accessed May 21, 2017.
48. Miller RF, Huang L, Walzer PD. Pneumocystis pneumonia associated with human immunodeficiency virus. Clin Chest Med. 2013;34(2):229-241. doi: 10.1016/j.ccm.2013.02.001.
49. CDC. DPDx - Laboratory Identification of Parasitic Diseases of Public Health Concern. Pneumocystis. May 3, 2016. ([Visit Source](#)). Accessed May 24, 2017.
50. CDC. Pneumococcal Disease. June 10, 2015. ([Visit Source](#)). Accessed May 21, 2017.
51. CDC. Rabies. April 22, 2011. ([Visit Source](#)). Accessed May 22, 2017.
52. Prasad, P. Respiratory syncytial virus in adults. DynaMed Plus. July 26, 2016. ([Visit Source](#)). Accessed May 22, 2017.
53. CDC. Fungal Diseases. December 6, 2015. ([Visit Source](#)). Accessed May 22, 2017.
54. CDC. Rocky Mountain Spotted Fever (RMSF). September 5, 2010. ([Visit Source](#)). Accessed May 22, 2017.
55. CDC. Rotavirus. August 12, 2016. ([Visit Source](#)). Accessed May 22, 2017.
56. CDC. Rubella (German Measles, Three-Day Measles). March 31, 2016. ([Visit Source](#)). Accessed May 22, 2017.
57. CDC. Parasites – Scabies. November 2, 2010. ([Visit Source](#)). Accessed May 22, 2017.
58. CDC. Group A Streptococcal (GAS) Disease. September 16, 2016. ([Visit Source](#)). Accessed May 22, 2017.
59. Sand FL, Thomsen SF. Skin disease of the vulva: Infectious disease. J Obstet Gynaecol, 2017 Apr 11:1-9. doi: 10.1080/01443615.2017.1306696. [Epub ahead of print]
60. Stamm LV. Syphilis: Re-emergence of an old foe. Microb Cell. 2016;3(9):363-370. doi: 10.15698/mic2016.09.523.
61. CDC. Sexually Transmitted Diseases (STDs). Syphilis – CDC Fact Sheet. February 24, 2017. ([Visit Source](#)). Accessed May 22, 2017.
62. CDC. Tetanus. January 10, 2017. ([Visit Source](#)). Accessed May 22, 2017.

63. CDC. Parasites - Trichinellosis (Also Known as Trichinosis). August 8, 2012. ([Visit Source](#)). Accessed May 22, 2017.
64. Jensen PA, Lambert LA, Iademarco MF, Ridzon R; CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep. 2005;54(RR-17):1-141.PIMD: 16382216
65. Van Zuuren, EJ. Enteric fever (Typhoid and paratyphoid). DynaMed Plus, March 31, 2017. ([Visit Source](#)). Accessed May 23, 2017.
66. CDC. Typhoid Fever. May 14, 2013. ([Visit Source](#)). May 22, 2107
67. CDC. Facility Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE). November 2015 Update – CRE Toolkit. April 18, 2017. ([Visit Source](#)). Accessed May 22, 2017.
68. Hayden MK, Lin MY, Lolans K, et al. Prevention of colonization and infection by Klebsiella pneumoniae carbapenemase-producing enterobacteriaceae in long-term acute-care hospitals. Clin Infect Dis. 2015;60(8):1153-1161. doi: 10.1093/cid/ciu1173.
69. CDC. Methicillin-Resistant Staphylococcus Aureus (MRSA). March 24, 2016. ([Visit Source](#)). Accessed May 22, 2017.
70. CDC. Investigation and Control of Vancomycin-Resistant Staphylococcus aureus: 2015 Update. April 2015. ([Visit Source](#)). Accessed May 22, 2017.
71. CDC. Vancomycin-Resistant Enterococci (VRE) in Healthcare Settings. May 10, 2011. ([Visit Source](#)). Accessed May 21, 2017.
72. Humphreys H. Measures to prevent and control vancomycin-resistant Enterococci: Do they really matter? Infect Control Hosp Epidemiol. 2017;38(4):507-509. doi: 10.1017/ice.2016.329.
73. CDC. Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. 2007. ([Visit Source](#)). Accessed May 22, 2017.
74. WHO. WHO Policy on TB Infection Control in Health-Care Facilities, Congregate Settings and Households. 2009. ([Visit Source](#)). Accessed May 22, 2017.
75. Elshafie S, Taj-Aldeen SJ. Emerging resistant serotypes of invasive Streptococcus pneumoniae. Infect Drug Resist. 2016;29(9):153-160. doi: 10.2147/IDR.S102410.
76. CDC. Pneumococcal Disease. Drug Resistance. June 10, 2015. ([Visit Source](#)). Accessed May 22, 2017.
77. Ainsworth S, Ketter PM, Yu JJ, et al. Vaccination with a live attenuated Acinetobacter baumannii deficient in thioredoxin provides protection against systemic Acinetobacter infection. Vaccine. 2017;35(26):3387-3394. doi:10.1016/j.vaccine.2017.05.017. Epub 2017 May 15.

78. Al-Gethamy MM, Faidah HS, Ademola HA, et al. Risk factors associated with multi-drug-resistant *Acinetobacter baumannii* nosocomial infections at a tertiary care hospital in Makkah, Saudi Arabia - a matched case-control study. *J Int Med Res.* 2017 Jan 1;300060517706284. doi: 10.1177/0300060517706284. [Epub ahead of print]
79. CDC. *Acinetobacter in Healthcare Settings.* November 24, 2010. ([Visit Source](#)). Accessed May 22, 2017.
80. Lashinsky JN, Henig O, Pogue JM, Kaye KS. Minocycline for the treatment of multidrug and extensively drug-resistant *A. baumannii*: A review. *Infect Dis Ther.* 2017 Mar 29. doi: 10.1007/s40121-017-0153-2. [Epub ahead of print]
81. Ying Q, Qun L, Qinzong L, Mingliang C, Hong C, Ni Z. Investigation and control of a suspected nosocomial outbreak of pan-drug resistant *Acinetobacter baumannii* in an intensive care unit. *Open Med (Wars).* 2016;11(1):587-592. doi: 10.1515/med-2016-0096.
82. CDC. *Safe Injection Practices to Prevent Transmission of Infections to Patients.* April 1, 2011. ([Visit Source](#)). Accessed May 22, 2017.
83. Kossover-Smith RA, Coutts K, Hatfield KM, et al. One needle, one syringe, only one time? A survey of physician and nurse knowledge, attitudes, and practices around injection safety. *Am J Infect Control.* 2017 Jun 15. pii: S0196-6553(17)30680-6. doi: 10.1016/j.ajic.2017.04.292. [Epub ahead of print]
84. CDC. *Respiratory Hygiene/Cough Etiquette in Healthcare Settings.* February 27, 2012. ([Visit Source](#)). Accessed May 22, 2017.
85. Zayas G, Chiang MC, Wong E, et al. Effectiveness of cough etiquette maneuvers in disrupting the chain of transmission of infectious respiratory diseases. *BMC Public Health.* 2013 Sep 8;13:811. doi: 10.1186/1471-2458-13-811.
86. Choi JS, Kim KM. Predictors of respiratory hygiene/cough etiquette in a large community in Korea: A descriptive study. *Am J Infect Control.* 2016;44(11): e271-e273. doi: 10.1016/j.ajic.2016.04.226.
87. CDC. *Sharps Safety for Healthcare Settings.* February 11, 2015. ([Visit Source](#)). Accessed May 24, 2017.
88. Kevitt F, Hayes B. Sharps injuries in a teaching hospital: changes over a decade. *Occup Med (Lond).* 2015;65(2):135-138. doi: 10.1093/occmed/kqu182.
89. Amini M, Behzadnia MJ, Saboori F, Bahadori M, Ravangard R. Needle-stick injuries among healthcare workers in a teaching hospital. *Trauma Mon.* 2015 Nov;20(4): e18829. doi: 10.5812/traumamon.18829. Epub 2015 Nov 23.
90. Motaarefi H, Mahmoudi H, Mohammadi E, Hasanpour-Dehkordi A. Factors associated with needle stick injuries in health care occupations: A systematic review. *J Clin Diagn Res.* 2016 Aug;10(8):IE01-IE04. doi:10.7860/JCDR/2016/17973.8221.

91. Frickmann H, Schmeja W, Reisinger E, et al. Risk reduction of needle stick injuries due to continuous shift from unsafe to safe instruments at a German university hospital. *Eur J Microbiol Immunol (Bp)*. 2016;6(3):227-237. eCollection 2016 Sep 29. DOI:10.1556/1886.2016.00025
92. Hambridge K, Nichols A, Endacott R The impact of sharps injuries on student nurses: a systematic review. *Br J Nurs*. 2016;25(19):1064-1071. DOI:10.12968/bjon.2016.25.19.1064
93. Green B, Griffiths EC. Psychiatric consequences of needle stick injury. *Occup Med (Lond)*. 2013;63(3):183-188. doi: 10.1093/occmed/kqt006. Epub 2013 Feb 21.
94. Zhang MX, Yu Y. A study of the psychological effects of sharps injuries on healthcare workers in China. *Am J Infec Control*. 2013;41(2):186-187. DOI: 10.1016/j.ajic.2012.02.023
95. Mitchell AH, Parker GB, Kanamori H, Rutala WA, Weber DJ. Comparing non-safety with safety device sharps injury incidence data from two different occupational surveillance systems. *J Hosp Infect*. 2017;96(2):195-198. doi:10.1016/j.jhin.2017.02.021. Epub 2017 Feb 27.
96. NIOSH. Alert: Preventing needle stick injuries in healthcare settings. DSSH NIOSH publication 2000 -1999. ([Visit Source](#)) Accessed May 25, 2017.
97. Choi LY, Torres R, Syed S, et al. Sharps and needle stick injuries among medical students, surgical residents, faculty, and operating room staff at a single academic institution. *J Surg Educ*. 2017;74(1):131-136. doi: 10.1016/j.jsurg.2016.06.003.
98. Hasak JM, Novak CB, Patterson JM, Mackinnon SE. Prevalence of needle stick Injuries, attitude changes, and prevention practices over 12 years in an urban academic hospital surgery department. *Ann Surg*. 2017 Feb 17. doi: 10.1097/SLA.0000000000002178. [Epub ahead of print]
99. Ouyang B, Li LD, Mount J, Jamal AJ, et al. Incidence and characteristics of needle stick injuries among medical trainees at a community teaching hospital: A cross-sectional study. *J Occup Health*. 2017;24;59(1):63-73. doi: 10.1539/joh.15-0253-FS.
100. Coyle JR, Goerge E, Kacynski K, et al. Hepatitis C virus infections associated with unsafe injection practices at a pain management clinic, Michigan, 2014-2015. *Pain Med*. 2016 Jul 17. pii: pnw157. [Epub ahead of print] DOI:10.1093/pm/pnw157
101. Dolan SA, Arias KM, Felizardo G, et al. APIC position paper: Safe injection, infusion, and medication vial practices in health care. *Am J Infect Control*. 2016;44(7):750-757. doi: 10.1016/j.ajic.2016.02.033.
102. Shastay AD. Evidence-based safe practice guidelines for I.V. push medications. *Nursing*. 2016;46(10):38-44. doi: 10.1097/01.NURSE.0000494641.31939.46
103. Scheithauer S, Batzer B, Dangel M, Passweg J, Widmer A. Workload even affects hand hygiene in a highly trained and well-staffed setting: a prospective 365/7/24

observational study. *J Hosp Infect*. 2017 Feb 20. pii: S0195-6701(17)30110-X. doi: 10.1016/j.jhin.2017.02.013. [Epub ahead of print]

104. Hagel S, Reischke J, Kesselmeier M, et al. Quantifying the Hawthorne effect in hand hygiene compliance through comparing direct observation with automated hand hygiene monitoring. *Infect Control Hosp Epidemiol*. 2015;36(8):957-962. doi: 10.1017/ice.2015.93.
105. World Health Organization (WHO). WHO Guidelines on Hand Hygiene in Healthcare. 2009. ([Visit Source](#)). Accessed May 27, 2017.
106. CDC. Hand Hygiene in Healthcare Settings. March 24, 2017. ([Visit Source](#)). Accessed May 29, 2017.
107. Deschênes P, Chano F, Dionne LL, Pittet D, Longtin Y. Efficacy of the World Health Organization-recommended handwashing technique and a modified washing technique to remove *Clostridium difficile* from hands. *Am J Infect Control*. 2017 May 16. pii: S0196-6553(17)30293-6. doi: 10.1016/j.ajic.2017.04.001. [Epub ahead of print]
108. Chun JY, Seo HK, Kim MK, et al. Impact of a hand hygiene campaign in a tertiary hospital in South Korea on the rate of hospital-onset methicillin-resistant *Staphylococcus aureus* bacteremia and economic evaluation of the campaign. *Am J Infect Control*. 2016;44(12):1486-1491. doi: 10.1016/j.ajic.2016.07.009.
109. Clark J, Henk JK, Crandall PG, Crandall MA, O'Bryan CA. An observational study of handwashing compliance in a child care facility. *Am J Infect Control*. 2016;44(12):1469-1474. doi: 10.1016/j.ajic.2016.08.006.
110. Stewardson AJ, Sax H, Gayet-Ageron A, et al. Enhanced performance feedback and patient participation to improve hand hygiene compliance of health-care workers in the setting of established multimodal promotion: a single-centre, cluster randomised controlled trial. *Lancet Infect Dis*. 2016;16(12):1345-1355. doi: 10.1016/S1473-3099(16)30256-0.
111. Kingston LM, Slevin BL, O'Connell NH, Dunne CP. Attitudes and practices of Irish hospital-based physicians towards hand hygiene and handrubbing using alcohol-based hand rubs, a comparison between 2007 and 2015. *J Hosp Infect*. 2017 May 19. pii: S0195-6701(17)30280-3. doi: 10.1016/j.jhin.2017.05.010. [Epub ahead of print]
112. Kaur R, Razee H, Seale H. Setting the right foundations: improving the approach used to teach concepts of hand hygiene to medical students. *J Hosp Infect*. 2017;95(4):355-358. doi: 10.1016/j.jhin.2017.01.006.
113. Luangasanatip N, Hongsuwan M, Limmathurotsakul D, et al. Comparative efficacy of interventions to promote hand hygiene in hospital: systematic review and network meta-analysis. *BMJ*. 2015 Jul 28;351:h3728. doi: 10.1136/bmj.h3728.
114. Boyce JM, Pittet D; Healthcare Infection Control Practices Advisory Committee; HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Guideline for Hand Hygiene in

Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep. 2002 Oct 25;51(RR-16):1-45, quiz CE1-4. PIMD: 12418624

115. WHO. Five moments for hand health hygiene. October 2006. [http://who.int/gpsc/tools/Five\\_moments/en/](http://who.int/gpsc/tools/Five_moments/en/). Accessed May 29, 2017.
116. Wilkinson MA, Ormandy K, Bradley CR, Fraise AP, Hines J. Dose considerations for alcohol-based hand rubs. *J Hosp Infect.* 2017;95(2):175-182. doi: 10.1016/j.jhin.2016.12.023.
117. Macinga DR, Shumaker DJ, Werner HP, et al. The relative influences of product volume, delivery format and alcohol concentration on dry-time and efficacy of alcohol-based hand rubs. *BMC Infect Dis.* 2014 Sep 20; 14:511. doi: 10.1186/1471-2334-14-511.
118. Bolon MK. Hand hygiene: An update. *Infect Dis Clin North Am.* 2016;30(3):591-607. doi: 10.1016/j.idc.2016.04.007.
119. Voss A, Widmer AF. No time for handwashing! Handwashing versus alcoholic rub: can we afford 100% compliance? *Infect Control Hosp Epidemiol.* 1997;18(3):205-208. PIMD: 9095051.
120. Hayden MK, Blom DW, Lyle EA, Moore CG, Weinstein RA. Risk of hand or glove contamination after contact with patients colonized with vancomycin-resistant enterococcus or the colonized patients' environment. *Infect Control Hosp Epidemiol.* 2008;29(2):149-154. doi: 10.1086/524331.
121. Wilson J, Bak A, Loveday HP. Applying human factors and ergonomics to the misuse of nonsterile clinical gloves in acute care. *Am J Infect Control.* 2017 Mar 29. pii: S0196-6553(17)30140-2. doi: 10.1016/j.ajic.2017.02.019. [Epub ahead of print]
122. Bardorf MH, Jäger B, Boeckmans E, Kramer A, Assadian O. Influence of material properties on gloves' bacterial barrier efficacy in the presence of microperforation. *Am J Infect Control.* 2016;44(12):1645-1649. doi:10.1016/j.ajic.2016.03.070.
123. Occupational Safety and Health Administration, 29 CFR. Standard 1910.1030 – Bloodborne Pathogens. December 6, 1991. ([Visit Source](#)). Accessed June 1, 2017.
124. Smith JD, MacDougall CC, Johnstone J, Copes RA, Schwartz B, Garber GE. Effectiveness of N95 respirators versus surgical masks in protecting health care workers from acute respiratory infection: a systematic review and meta-analysis. *CMAJ.* 2016;188(8):567-574. doi: 10.1503/cmaj.150835.
125. Neilson S. The surgical mask is a bad fit for risk reduction. *CMAJ.* 2016 Apr 11. pii: cmaj.151236. [Epub ahead of print]. DOI: 10.1503/cmaj.151236.
126. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Aug. CADTH Rapid Response Reports. Respiratory precautions for protection from



bioaerosols or infectious agents: A review of the clinical effectiveness and guidelines [Internet]. PMID: 25411668.

127. Verbeek JH, Ijaz S, Mischke C, et al. Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff. *Cochrane Database Syst Rev*. 2016 Apr 19;4:CD011621. doi: 10.1002/14651858.CD011621.pub2.
128. Roberge RJ. Face shields for infection control: A review. *J Occup Environ Hyg*. 2016;13(4):235-242. doi: 10.1080/15459624.2015.1095302.
129. Lindsley WG, Noti JD, Blachere FM, Szalajda JV, Beezhold DH. Efficacy of face shields against cough aerosol droplets from a cough simulator. *J Occup Environ Hyg*. 2014;11(8):509-518. doi: 10.1080/15459624.2013.877591.
130. Kilinc FS. A review of isolation gowns in healthcare: Fabric and gown properties. *J Eng Fiber Fabr*. 2015;10(3):180-190. PMID: 26989351.
131. Food and Drug Administration. Medical Gowns. May 10, 2016. ([Visit Source](#)). Accessed June 1, 2017.
132. Kilinc Balci FS. Isolation gowns in health care settings: Laboratory studies, regulations and standards, and potential barriers of gown selection and use. *Am J Infect Control*. 2016;44(1):104-111. doi: 10.1016/j.ajic.2015.07.042.132. Seto WH. Airborne transmission and precautions: facts and myths. *J Hosp Infect*. 2015;89(4):225-228. doi: 10.1016/j.jhin.2014.11.005.
133. Food and Drug Administration. Masks and N95 Respirators. June 26, 2016. ([Visit Source](#)). Accessed June 2, 2017.
134. Occupational Safety and Health Administration. Fit Testing Procedures (Mandatory). 1910.134 App A. April 23, 1998. ([Visit Source](#)). Accessed June 2, 2017.
135. CDC. Pandemic Planning. Recommended Guidance for Extended Use and Limited Reuse of N95 Filtering Facepiece Respirators in Healthcare Settings. March 13, 2014. ([Visit Source](#)). Accessed June 2, 2017.
136. Wei J, Li Y. Airborne spread of infectious agents in the indoor environment. *Am J Infect Control*. 2016;44(9 Suppl): S102-S108. doi: 10.1016/j.ajic.2016.06.003.
137. CDC. Prevention Strategies for Seasonal Influenza In Healthcare Settings. October 5, 2016. ([Visit Source](#)). Accessed June 2, 2017.
138. Isenman H, Michaels J, Fisher D. Global variances in infection control practices for vancomycin resistant Enterococcus - results of an electronic survey. *Antimicrob Resist Infect Control*. 2016 Nov 3;5:41. eCollection 2016. DOI:10.1186/s13756-016-0140-5
139. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in health



care settings, 2006. *Am J Infect Control*. 2007;35(10 Suppl 2): S165-S93. DOI: 10.1016/j.ajic.2007.10.006

140. Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. *MMWR Recomm Rep*. 2009 Sep 4;58(RR-11):1-166. PMID: 19730409.
141. Lequilliec N, Raymond R, Vanjak D. Practices of infectious control management during neutropenia: A survey from 149 French hospitals. *J Mycol Med*. 2017 Mar 14. pii: S1156-5233(17)30018-5. doi: 10.1016/j.mycmed.2017.02.006. [Epub ahead of print]
142. Beam E, Keating MR, Razonable RR. A survey of infection prevention and control practices among hematopoietic stem cell transplant centers. *Infect Control Hosp Epidemiol*. 2016;37(3):348-351. doi: 10.1017/ice.2015.280.
143. Advisory Committee on Immunization Practices; Centers for Disease Control and Prevention (CDC). Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2011 Nov 25;60(RR-7):1-45. PMID: 22108587.
144. Wingard JR. Prevention of infections in hematopoietic cell transplant recipients. UpToDate. December 1, 2016. ([Visit Source](#)). Accessed July 5, 2017.
145. Rutala WA, Weber DJ, and the Healthcare Infection Control Practices Advisory Committee (HICPAC). Guideline for Sterilization and Disinfection in Healthcare Facilities, 2008. November 2008. ([Visit Source](#)). Accessed June 5, 2017.
146. Rutala WA, Weber DJ. Disinfection and sterilization in health care facilities: An overview and current issues. *Infect Dis Clin North Am*. 2016;30(3):609-637. doi: 10.1016/j.idc.2016.04.002.
147. Fisher A, Dembry LM. Norovirus and Clostridium difficile outbreaks: squelching the wildfire. *Curr Opin Infect Dis*. 2017 May 22. doi: 10.1097/QCO.0000000000000382. [Epub ahead of print]
148. Neves MS, da Silva MG, Ventura GM, et al. Effectiveness of current disinfection procedures against biofilm on contaminated GI endoscopes. *Gastrointest Endosc*. 2016;83(5):944-953. doi: 10.1016/j.gie.2015.09.016.
149. Ofstead CL, Wetzler HP, Eiland JE, Heymann OL, Held SB, Shaw MJ. Assessing residual contamination and damage inside flexible endoscopes over time. *Am J Infect Control*. 2016;44(12):1675-1677. doi: 10.1016/j.ajic.2016.06.029.
150. Ofstead CL, Wetzler HP, Heymann OL, Johnson EA, Eiland JE, Shaw MJ. Longitudinal assessment of reprocessing effectiveness for colonoscopes and

gastrosopes: Results of visual inspections, biochemical markers, and microbial cultures. *Am J Infect Control*. 2017;45(2):e26-e33. doi: 10.1016/j.ajic.2016.10.017.

151. CDC. Essential Elements of a Reprocessing Program for Flexible Endoscopes – Recommendations of the Healthcare Infection Control Practices Advisory Committee. January 25, 2017. ([Visit Source](#)). Accessed June 14, 2017.
152. ASGE Quality Assurance in Endoscopy Committee, Petersen BT, Chennat J, et al. Multisociety guidelines on reprocessing flexible gastrointestinal endoscopes: 2011. *Gastrointest Endosc*. 2011;73(6):1075-1084. doi:10.1016/j.gie.2011.03.1183.
153. Petersen BT, Chennat J, Cohen J, et al. Multi-society guideline on reprocessing flexible GI endoscopes: 2011. *Infect Control Hosp Epidemiol* 2011;32(6):527–537. doi: 10.1086/660676.
154. Society of Gastroenterology Nurses and Associates. Standards of infection control in reprocessing of flexible gastrointestinal endoscopes. *Gastroenterol Nurs*. 2013;36(4):293-303. doi: 10.1097/SGA.0b013e31829c6d5b.
155. Leroy S. Infectious risk of endovaginal and transrectal ultrasonography: systematic review and meta-analysis. *J Hosp Infect*. 2013;83(2):99-106. doi: 10.1016/j.jhin.2012.07.014.
156. Gallay C, Miranda E, Schaefer S, et al. Human papillomavirus (HPV) contamination of gynaecological equipment. *Sex Transm Infect*. 2016;92(1):19-23. doi: 10.1136/sextrans-2014-051977.
157. Omar Akhtar A, Singh H, Si F, Hodge WG. A systematic review and cost-effectiveness analysis of tonometer disinfection methods. *Can J Ophthalmol*. 2014;49(4):345-350. doi: 10.1016/j.jcjo.2014.04.003.
158. Leroy S, M'Zali F, Kann M, Weber DJ, Smith DD. Impact of vaginal-rectal ultrasound examinations with covered and low-level disinfected transducers on infectious transmissions in France. *Infect Control Hosp Epidemiol*. 2014;35(12):1497-1504. doi: 10.1086/678604.
159. Westerway SC, Basseal JM, Brockway A, Hyett JA, Carter DA. Potential Infection control risks associated with ultrasound equipment - A bacterial perspective. *Ultrasound Med Biol*. 2017;43(2):421-426. doi: 10.1016/j.ultrasmedbio.2016.09.004. Epub 2016 Oct 26.
160. Merz E. Is Transducer hygiene sufficient when vaginal probes are used in the clinical routine? *Ultraschall Med*. 2016;37(2):137-139. doi: 10.1055/s-0042-103605.
161. Smart JD, Belkoff SM, Mears SC. The effectiveness of a program to reduce the rate of flash sterilization. *J Arthroplasty*. 2012;27(7):1267-1270. doi: 10.1016/j.arth.2011.10.028.

162. Foster S, Sullivan SC, Brandt J. Code flash: how an interdisciplinary team eradicated immediate-use steam sterilization. *Infect Control Hosp Epidemiol*. 2015;36(1):112-113. doi: 10.1017/ice.2014.18.
163. Hutzler L, Kraemer K, Iaboni L, Berger N, Bosco JA 3rd. A hospital-wide initiative to eliminate preventable causes of immediate use steam sterilization. *AORN J*. 2013;98(6):597-607. doi: 10.1016/j.aorn.2013.10.006.
164. Joint Commission. Instrument Reprocessing - Immediate Use Steam Sterilization (IUSS). May 12, 2017. ([Visit Source](#)). Accessed June 17, 2017.
165. Graybill-D'Ercole P. Implementing AORN recommended practices for sterilization. *AORN J*. 2013;97(5):521-533. doi: 10.1016/j.aorn.2013.03.002.
166. Food and Drug Administration. Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling Guidance for Industry and Food and Drug Administration Staff. March 17, 2015. ([Visit Source](#)). Accessed June 17, 2017.
167. Fedorowicz Z. Ebola virus disease. *DynaMed Plus*. February 22, 2017. ([Visit Source](#)). Accessed June 17, 2017.
168. CDC. Ebola (Ebola Virus Disease). September 22, 2015. ([Visit Source](#)). Accessed June 17, 2017.
169. Ko S, An HS, Bang JH, Park SW. An outbreak of Burkholderia cepacia complex pseudobacteremia associated with intrinsically contaminated commercial 0.5% chlorhexidine solution. *Am J Infect Control*. 2015;43(3):266-268. doi:10.1016/j.ajic.2014.11.010.
170. Weber DJ, Rutala WA, Sickbert-Bennett EE. Outbreaks associated with contaminated antiseptics and disinfectants. *Antimicrob Agents Chemother*. 2007;51(12):4217-424. DOI: 10.1128/AAC.00138-07
171. Danchaivijitr S, Dhiraputra C, Rongrungruang Y, Srihapol N, Pumsuwan V. Microbial contamination of antiseptics and disinfectants. *J Med Assoc Thai*. 2005;88 Suppl 10: S133-S139. PMID: 16850658.
172. Vonberg RP, Gastmeier P. Hospital-acquired infections related to contaminated substances. *J Hosp Infect*. 2007; 65(1):15-23. DOI: 10.1016/j.jhin.2006.09.018.
173. Pokala HR, Leonard D, Cox J, Metcalf P, McClay J, Siegel J, Winick N. Association of hospital construction with the development of healthcare associated environmental mold infections (HAEMI) in pediatric patients with leukemia. *Pediatr Blood Cancer*. 2014;61(2):276-280. doi: 10.1002/pbc.24685.
174. Berger J, Willinger B, Diab-Elschahawi M, Blacky A, Kalhs P, Koller W, Assadian O, Aichberger KJ. Effectiveness of preventive measures for hemato-oncologic patients undergoing stem cell transplantation during a period of hospital construction. *Am J Infect Control*. 2011;39(9):746-751. doi: 10.1016/j.ajic.2011.01.011.

175. Schulster L, Chinn RY; CDC; HICPAC. Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep. 2003 Jun 6;52(RR-10):1-42. PMID: 12836624
176. Joint Commission. Joint Commission Online. Patient Safety – The Role of HVAC Systems in Preserving Patient Safety. August 20, 2014. ([Visit Source](#)). Accessed June 17, 2017
177. Centers for Disease Control and Prevention. Division of Oral Health. Summary of Infection Prevention Practices in Dental Settings: Basic Expectations for Safe Care, Atlanta, GA: Centers for Disease Control and Prevention, US Dept of Health and Human Services; October 2016. ([Visit Source](#)). Accessed June 14, 2017.
178. Weaver JM. Confirmed transmission of hepatitis C in an oral surgery office. Anesth Prog. 2014;61(3):93-94. doi: 10.2344/0003-3006-61.3.93.
179. Sebastiani FR, Dym H, Kirpalani T. Infection control in the dental office. Dent Clin North Am. 2017;61(2):435-457. doi: 10.1016/j.cden.2016.12.008.
180. File TM. Risk factors and prevention of hospital-acquired and ventilator-associated pneumonia in adults. UpToDate. September 27, 2016. ([Visit Source](#)). Accessed June 17, 2017.
181. Pássaro L, Harbarth S, Landelle C. Prevention of hospital-acquired pneumonia in non-ventilated adult patients: a narrative review. Antimicrob Resist Infect Control. 2016 Nov 14;5:43. eCollection 2016. DOI:10.1186/s13756-016-0150-3
182. Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R; CDC; Healthcare Infection Control Practices Advisory Committee. Guidelines for preventing health-care--associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep. 2004;53(RR-3):1-36.
183. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388-416. DOI: 10.1164/rccm.200405-644ST
184. Institute for Healthcare Improvement. How-To Guide: Prevent Ventilator-Associated Pneumonia.2012. www.ihp.org.
185. Mitchell RB, Hussey HM, Setzen G, et al. Clinical consensus statement – Tracheostomy care. Otolaryngol Head Neck Surg. 2013;148(1):6-20. doi: 10.1177/0194599812460376.
186. Sodhi K, Shrivastava A, Singla MK. Implications of dedicated tracheostomy care nurse program on outcomes. J Anesth. 2014;28(3):374-380. doi: 10.1007/s00540-013-1718-1.

187. Hamishekar H, Shadvar K, Taghizadeh M. Ventilator-associated pneumonia in patients admitted to intensive care units, using open or closed endotracheal suctioning. *Anesth Pain Med.* 2014;4(5): e21649. doi: 10.5812/aapm.21649.
188. Kuriyama A, Umakoshi N, Fujinaga J, Takada T. Impact of closed versus open tracheal suctioning systems for mechanically ventilated adults: a systematic review and meta-analysis. *Intensive Care Med.* 2015;41(3):402-411. doi: 10.1007/s00134-014-3565-4.
189. Li Bassi G. Airway secretions and suctioning. In: Tobin MJ, ed. *Principles and Practice of Mechanical Ventilation.* New York, NY: McGraw-Hill; 2013. Accessed June 17, 2017 from [www.UCHC.edu](http://www.UCHC.edu).
190. Leddy R, Wilkinson JM. Endotracheal suctioning practices of nurses and respiratory therapists: How well do they align with clinical practice guidelines? *Can J Respir Ther.* 2015;51(3):60-64. PMID: 26283870.
191. Kobayashi M, Bennett NM, Gierke R, et al. Intervals between PCV13 and PPSV23 vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep.* 2015;64(34):944-947.
192. Nuorti JP, Whitney CG; Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children: use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine: recommendations of the Advisory Committee Immunization Practices (ACIP). *MMWR Recomm Rep.* 2010;59(RR-11):1-18.
193. Tomczyk S, Bennett NM, Stoecker C, et al; Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged  $\geq 65$  years: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep.* 2014;63(37):822-825.
194. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep.* 2013;62(25):521-524.
195. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep.* 2012;61(40):816-819.

196. Kaya H, Turan Y, Tunali Y, et al. Effects of oral care with glutamine in preventing ventilator-associated pneumonia in neurosurgical intensive care unit patients. *Appl Nurs Res.* 2017; 33:10-14. doi: 10.1016/j.apnr.2016.10.006.
197. Akdogan O, Ersoy Y, Kuzucu C, Gedik E, Tugal T, Yetkin F. Assessment of the effectiveness of a ventilator associated pneumonia prevention bundle that contains endotracheal tube with subglottic drainage and cuff pressure monitorization. *Braz J Infect Dis.* 2017;21(3):276-281. doi: 10.1016/j.bjid.2017.01.002.
198. Okgun Alcan A, Yavuz van Giersbergen M, Dincarslan G, Hepcivici Z, Kaya E, Uyar M. Effect of patient position on endotracheal cuff pressure in mechanically ventilated critically ill patients. *Aust Crit Care.* 2016 Dec 16. pii: S1036-7314(16)30185-0. doi: 10.1016/j.aucc.2016.11.006. [Epub ahead of print]
199. Critical Care Nurse. [No authors listed]. Prevention of aspiration in adults. *Crit Care Nurse.* 2016;36(1):e20-e4. doi: 10.4037/ccn2016831.
200. Taylor BE, McClave SA, Martindale RG, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). *Crit Care Med.* 2016;44(2):390-438. doi: 10.1097/CCM.0000000000001525.
201. Hodin RA, Bordeianou L. Nasogastric and nasoenteric tubes. UpToDate. November 16, 2015. ([Visit Source](#)). Accessed June 18, 2017.
202. Bennetzen LV, Håkonsen SJ, Svenningsen H, Larsen P. Diagnostic accuracy of methods used to verify nasogastric tube position in mechanically ventilated adult patients: a systematic review. *JBI Database System Rev Implement Rep.* 2015;13(1):188-223. doi: 10.11124/jbisrir-2015-1609.
203. Tang HJ, Chao CM, Leung PO, Lai CC. An observational study to compare oral hygiene care with chlorhexidine gluconate gel versus mouthwash to prevent ventilator-associated pneumonia. *Infect Control Hosp Epidemiol.* 2017;38(5):631-632. doi: 10.1017/ice.2017.24.
204. 204. Ory J, Raybaud E, Chabanne R, et al. Comparative study of 2 oral care protocols in intensive care units. *Am J Infect Control.* 2017;45(3):245-250. doi: 10.1016/j.ajic.2016.09.006.
205. Hua F, Xie H, Worthington HV, Furness S, Zhang Q, Li C. Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia. *Cochrane Database Syst Rev.* 2016 Oct 25;10:CD008367. DOI:10.1002/14651858.CD008367.pub3.
206. Sharif-Abdullah SS, Chong MC, Surindar-Kaur SS, Kamaruzzaman SB, Ng KH. The effect of chlorhexidine in reducing oral colonisation in geriatric patients: a randomised controlled trial. *Singapore Med J.* 2016;57(5):262-266. doi: 10.11622/smedj.2016091.

207. Zuckerman LM. Oral chlorhexidine used to prevent ventilator-associated pneumonia in adults: Review of the current literature. *Dimens Crit Care Nurs.* 2016;35(1):25-36. doi: 10.1097/DCC.000000000000154.
208. Chacko R, Rajan A, Lionel P, Thilagavathi M, Yadav B, Premkumar J. Oral decontamination techniques and ventilator-associated pneumonia. *Br J Nurs.* 2017;26(11):594-599. doi: 10.12968/bjon.2017.26.11.594.
209. Kusahara DM, Peterlini MA, Pedreira ML Oral care with 0.12% chlorhexidine for the prevention of ventilator-associated pneumonia in children: randomized, controlled and double-blind trial. *Int J Nurs Stud.* 2012;49(11):1354-1363. doi:10.1016/j.ijnurstu.2012.06.005.
210. Nicolosi LN, del Carmen Rubio M, Martinez CD, González NN, Cruz ME. Effect of oral hygiene and 0.12% chlorhexidine gluconate oral rinse in preventing ventilator-associated pneumonia after cardiovascular surgery. *Respir Care.* 2014;59(4):504-509. doi: 10.4187/respcare.02666.
211. Weinhouse GL. Stress ulcer prophylaxis in the intensive care unit. UpToDate. August 25, 2015. ([Visit Source](#)). Accessed June 18, 2017.
212. Pfeifer K, Smetana GW. Perioperative pulmonary risk assessment and management. In: McKean SC, Ross JJ, Dressler DD, Scheurer, eds. *Principles and Practice of Hospital Medicine*, 2nd ed. New York, NY: McGraw-Hill Education; 2017. Accessed June 18, 2017 from [www.UCHC.edu](http://www.UCHC.edu)
213. Kazaure HS, Martin M, Yoon JK, Wren SM. Long-term results of a postoperative pneumonia prevention program for the inpatient surgical ward. *JAMA Surg.* 2014;149(9):914-918. doi: 10.1001/jamasurg.2014.1216.
214. Pusey-Reid E. Preventing post-operative pneumonia. *Nurs Crit Care.* 2014;9(4):42-47. DOI: 10.1097/01.CCN.0000451019.99949.12
215. Li Bassi G, Senussi T, Aguilera Xiol E. Prevention of ventilator-associated pneumonia. *Curr Opin Infect Dis.* 2017;30(2):214-220. doi: 10.1097/QCO.0000000000000358.
216. OSHA. Legionnaire's Disease. Frequently Asked Questions. ([Visit Source](#)). Accessed June 18, 2017.
217. CDC. Legionella (Legionnaires' Disease and Pontiac Fever), Disease Specifics. June 1, 2017. ([Visit Source](#)). Accessed June 18, 2017.
218. Cunha BA, Burillo A, Bouza E. Legionnaires' disease. *Lancet.* 2016;387(10016):376-85. doi: 10.1016/S0140-6736(15)60078-2
219. CDC. Legionella (Legionnaires' Disease and Pontiac Fever), Diagnosis, Treatment, and Prevention. June 1, 2017. ([Visit Source](#)). Accessed June 18, 2017.



220. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis*. 2007;44 Suppl 2: S27-S72. DOI:10.1086/511159.
221. Parr A., Whitney E.A., Berkelman R.L. Legionellosis on the rise: A review of guidelines for prevention in the United States. *J Public Health Manag Pract*. 2015;21(5):E17-26. doi: 10.1097/PHH.000000000000123.
222. Whiley H. Legionella risk management and control in potable water systems: Argument for the abolishment of routine testing. *Int J Environ Res Public Health*. 2016 Dec 24;14(1). pii: E12. doi: 10.3390/ijerph14010012.
223. Yeh S. Pertussis infection in infants and children: Treatment and prevention. UpToDate. April 25, 2017. ([Visit Source](#)). Accessed June 19, 2017.
224. ACIP Adult Immunization Work Group, Bridges CB, Woods L, Coyne-Beasley T; Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older--United States, 2013. *MMWR Suppl*. 2013;62(1):9-19. PMID: 23364303
225. CDC. Vaccines and Preventable Diseases. Diphtheria, Tetanus, and Pertussis Vaccine Recommendations. November 22, 2016. ([Visit Source](#)). Accessed June 19, 2017.
226. CDC. Vaccines and Preventable Diseases. Pertussis: Summary of Vaccine Recommendations. June 22, 2016. ([Visit Source](#)). Accessed June 19, 2017.
227. CDC. Pertussis (Whooping Cough). Post-exposure Antimicrobial Prophylaxis. September 8, 2015. ([Visit Source](#)). Accessed June 19, 2017.
228. Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2016;63(4):e1-e60. doi: 10.1093/cid/ciw326.
229. Abdul Salam ZH, Karlin RB, Ling ML, Yang KS. The impact of portable high-efficiency particulate air filters on the incidence of invasive aspergillosis in a large acute tertiary-care hospital. *Am J Infect Control*. 2010;38(4):e1-e7. doi: 10.1016/j.ajic.2009.09.014.
230. Combariza JF, Toro LF, Orozco JJ. Effectiveness of environmental control measures to decrease the risk of invasive aspergillosis in acute leukaemia patients during hospital building work. *J Hosp Infect*. 2017 May 5. pii: S0195-6701(17)30238-4. doi: 10.1016/j.jhin.2017.04.022. [Epub ahead of print]
231. Chang CC, Ananda-Rajah M, Belcastro A, et al. Consensus guidelines for implementation of quality processes to prevent invasive fungal disease and enhanced surveillance measures during hospital building works, 2014. *Intern Med J*. 2014;44(12b):1389-1397. doi: 10.1111/imj.12601.



232. Marr KA. Epidemiology and clinical manifestations of invasive aspergillosis. UpToDate, December 22, 2015. ([Visit Source](#)). Accessed June 19, 2017.
233. Dolin R. Common viral respiratory infections. In: Kasper D, Fauci A, Hauser S, Long D, Jameson JL, Loscalzo J, eds. Harrison's Principles of Internal Medicine, 19th ed. New York, NY: McGraw-Hill, 2015. Online edition, accessed June 21, 2017 from [www.UCHC.edu](http://www.UCHC.edu).
234. Inkster T, Ferguson K, Edwardson A, Gunson R, Soutar R. Consecutive yearly outbreaks of respiratory syncytial virus in a haemato-oncology ward and efficacy of infection control measures. *J Hosp Infect*. 2017 May 6. pii: S0195-6701(17)30266-9. doi: 10.1016/j.jhin.2017.05.002. [Epub ahead of print]
235. Hoyle E, Erez JC, Kirk-Granger HR, Collins E, Tang JW. An adenovirus 4 outbreak amongst staff in a pediatric ward manifesting as keratoconjunctivitis—a possible failure of contact and aerosol infection control. *Am J Infect Control*. 2016;44(5):602-4. doi: 10.1016/j.ajic.2015.11.032.
236. CDC. Human Parainfluenza Viruses. Clinical overview. August 8, 2015. ([Visit Source](#)). Accessed June 21, 2017.
237. CDC. Adenoviruses. Prevention and Treatment. January 4, 2017. ([Visit Source](#)). Accessed June 21, 2017.
238. CDC. Respiratory Syncytial Virus Infection (RSV). RSV Prevention. March 7, 2017. ([Visit Source](#)). Accessed June 1, 2017.
239. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. *Pediatrics*. 2014;134(2):415-420. doi: 10.1542/peds.2014-1665.
240. Eibach D, Casalegno JS, Bouscambert M, et al. Routes of transmission during a nosocomial influenza A(H3N2) outbreak among geriatric patients and healthcare workers. *J Hosp Infect*. 2014;86(3):188-193. doi: 10.1016/j.jhin.2013.11.009.
241. Pless A, McLennan SR, Nicca D, Shaw DM, Elger BS. Reasons why nurses decline influenza vaccination: a qualitative study. *BMC Nurs*. 2017 Apr 28;16:20. doi: 10.1186/s12912-017-0215-5. eCollection 2017.
242. Smith S, Sim J, Halcomb E. Nurses' knowledge, attitudes and practices regarding influenza vaccination: an integrative review. *J Clin Nurs*. 2016;25(19-20):2730-2744. doi: 10.1111/jocn.13243.
243. Pless A, Shaw D, McLennan S, Elger BS. Nurses' attitudes towards enforced measures to increase influenza vaccination: A qualitative study. *Influenza Other Respir Viruses*. 2017;11(3):247-253. doi: 10.1111/irv.12441.

244. CDC. Influenza (Flu). Prevention Strategies for Seasonal Influenza in Healthcare Settings. October 5, 2016. ([Visit Source](#)) Accessed June 21, 2017.
245. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines. *MMWR Recomm Rep.* 2016;65(5):1-54. doi: 10.15585/mmwr.rr6505a1.
246. CDC. Influenza (Flu). Influenza Antiviral Medications: Summary for Clinicians. March 8, 2017. ([Visit Source](#)). Accessed June 21, 2017.
247. CDC. Interim Guidance for Influenza Outbreak Management in Long-Term Care Facilities. March 28, 2017. ([Visit Source](#)). Accessed June 21, 2017.
248. Weber DJ, Rutala WA, Eron J. Prevention of hepatitis B virus and hepatitis C virus among healthcare providers. *UpToDate.* April 6, 2015. ([Visit Source](#)). Accessed June 22, 2017.
249. Bartlett JG, Weber DJ. Management of healthcare personnel exposed to HIV. *UpToDate.* May 20, 2015. ([Visit Source](#)). Accessed July 1, 2017.
250. Fauci AS, Lane HC. Human immunodeficiency virus disease: AIDS and related disorders. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson JL, Loscalzo J, eds. *Harrison's Principles of Internal Medicine*, 19e. New York, NY: McGraw-Hill Education; 2015. Online edition, Accessed June 23, 2017, [www.UCHC.edu](http://www.UCHC.edu).
251. Sin WW, Lin AW, Chan KC, Wong KH. Management of health care workers following occupational exposure to hepatitis B, hepatitis C, and human immunodeficiency virus. *Hong Kong Med J.* 2016 Oct;22(5):472-7. DOI: 10.12809/hkmj164897.
252. U.S. Public Health Service. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Post-exposure Prophylaxis. *MMWR Recomm Rep.* 2001;50(RR-11):1-52. PMID: 11442229.
253. Egro FM, Nwaiwu CA, Smith S, Harper JD, Spiess AM. Seroconversion rates among health care workers exposed to hepatitis C virus-contaminated body fluids: The University of Pittsburgh 13-year experience. *Am J Infect Control.* 2017 Apr 24. pii: S0196-6553(17)30209-2. doi: 10.1016/j.ajic.2017.03.011. [Epub ahead of print]
254. Kuhar DT, Henderson DK, Struble KA, Heneine W, Thomas V, Cheever LW, US Public Health Service Working Group, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for post-exposure prophylaxis. *Infect Control Hosp Epidemiol.* 2013;34(9): 875–892. doi: 10.1086/672271.
255. Nwaiwu CA, Egro FM, Smith S, Harper JD, Spiess AM. Seroconversion rate among health care workers exposed to HIV-contaminated body fluids: The University of

- Pittsburgh 13-year experience. *Am J Infect Control*. 2017 Apr 24. pii: S0196-6553(17)30234-1. doi: 10.1016/j.ajic.2017.03.012. [Epub ahead of print]
256. Naggie S, Holland DP, Sulkowski MS, Thomas DL. Hepatitis C virus post-exposure prophylaxis in the healthcare worker: Why direct-acting antivirals don't change a thing. *Clin Infect Dis*. 2017;64(1):92-99. DOI:10.1093/cid/ciw656.
257. Hughes HY, Henderson DK. Post-exposure prophylaxis after hepatitis C occupational exposure in the interferon-free era. *Curr Opin Infect Dis*. 2016;29(4):373-380. doi: 10.1097/QCO.0000000000000281.
258. Neviere, R. Sepsis syndrome in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis. UpTo Date. ([Visit Source](#).) Updated June 12, 2018, Accessed August 29, 2018
259. Rhodes, A., Evans, L., Alhazzani, W., et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock. *Intensive Care Med*. 2017;43(3):304-377.doi: 10.1007/s00134-017-4683-6.
260. Neviere, R. Pathophysiology of sepsis. UpToDate. ([Visit Source](#)).
261. Gotur, DB. Sepsis in a Panorama: What the Cardiovascular Physician Should Know. 2018;14(2):89-100. doi: 10.14797/mdcj-14-2-89
262. Rhee, C., Dantes, R., Epstein, L., et al. (2017). Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. *JAMA*, 318(13):1241-1249.
263. Envier, 2018 (retrieving reference)
264. New York State Department of Health. (2017). New York State Report on Sepsis Care Improvement Initiative: Hospital Quality Performance. Revised June 2017. Accessed August 29, 2018 from ([Visit Source](#))
265. New York State. New York State Education Law. Sec. 6505-B Course Work or Training in Infection Control Practices Accessed August 28, 2018 from ([Visit Source](#)).
266. Seymour, C.W., Gesten, F., Prescott. H., et al: (2017). Time to treatment and mortality during mandated emergency care for sepsis. *New England Journal of Medicine*,376(23): 2235–2244.
267. Pomerantz, W.J., Weiss, S.S. (2018). Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis. *UpToDate*. Accessed August 28, 2018 from ([Visit Source](#)).
268. Kelley, M.A. (2018). Predictive scoring systems in the intensive care unit. *UpToDate*. Accessed August 28, 2018 from ([Visit Source](#)).
269. Kalil, A. (2018). Septic shock. eMedicine. Accessed August 28, 2018 ([Visit Source](#)).
270. Centers for Disease Control and Prevention. (2017). CDC urges early recognition, prompt treatment of sepsis. Accessed August 28, 2018 ([Visit Source](#)).

271. Jabaley, C.S., Blum, J.M., Groff, R.F., O'Reilly-Shah, V.N. (2018). Global trends in the awareness of sepsis: insights from search engine data between 2012 and 2017. *Critical Care*, Jan 17;22(1):7. doi: 10.1186/s13054-017-1914-8.
272. Sepsis Alliance. Accessed August 28, 2018 from Sepsis Alliance ([Visit Source](#)).